Chromic Chloride
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Chromic Chloride: From Trace Element Supplement to Primary Hereditary Glaucoma
One-Sentence Summary
Chromic chloride is a chromium(III) inorganic compound, primarily used as a trace element additive in parenteral nutrition to meet chromium requirements in patients receiving total parenteral nutrition (TPN). The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, with a prediction score of 95.70%. However, there are currently no clinical trials and no published literature supporting this direction — the evidence level is L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Trace element supplementation (parenteral nutrition) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 95.70% |
| Evidence Level | L5 — Model prediction only, no supporting studies |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, chromic chloride is an inorganic chromium(III) salt serving as a source of the essential trace element chromium. Its established role is in insulin signalling — chromium(III) enhances insulin receptor sensitivity, potentially improving glucose metabolism, reducing insulin resistance, and modulating lipid profiles.
Primary hereditary glaucoma is a genetically driven disorder characterised by elevated intraocular pressure (IOP) due to dysfunction in trabecular meshwork outflow, often linked to mutations in genes such as MYOC, OPTN, or CYP1B1. There is no established biological connection between chromium(III) and aqueous humour dynamics, trabecular meshwork function, or optic nerve protection. The TxGNN model may have captured indirect multi-hop paths in the knowledge graph — for example, chromium → mitochondrial function → oxidative stress → optic nerve integrity — but these are speculative connections without direct experimental support.
In summary, while chromium's metabolic effects are reasonably well-characterised, a plausible mechanistic bridge to primary hereditary glaucoma is currently lacking. The high TxGNN score (95.70%) likely reflects proximity within the knowledge graph rather than a direct pharmacological relationship. This prediction should be regarded with considerable caution.
Clinical Trial Evidence
Currently no related clinical trials registered for Chromic Chloride in primary hereditary glaucoma.
Literature Evidence
Currently no related literature available for Chromic Chloride in primary hereditary glaucoma.
Singapore Market Information
Chromic chloride is currently not registered in Singapore. No authorisation records are available.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction data, key warnings, or contraindication records were retrievable for this evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 predicted indications in this Evidence Pack are rated L5 with an S0 decision stage, meaning the TxGNN model prediction is the sole basis — no clinical trials, no published literature, and no established mechanistic link support chromic chloride's use in primary hereditary glaucoma or any of the other predicted conditions. The drug is also not registered in Singapore, providing no regulatory foundation to build upon.
To proceed, the following would be needed:
- Establish mechanistic plausibility: Conduct a structured literature review to determine whether any peer-reviewed research connects chromium(III) compounds to intraocular pressure regulation, trabecular meshwork biology, or optic nerve neuroprotection.
- Retrieve full safety data: Obtain and parse the Singapore HSA package insert (if available internationally) or equivalent regulatory documents to assess warnings, contraindications, and drug interactions before any clinical consideration.
- Obtain MOA data from DrugBank: Query DrugBank API for the full pharmacology profile of DB09129 to better characterise mechanism-of-action and pharmacokinetic properties relevant to ocular bioavailability.
- Consider alternative chromium forms: If a mechanistic hypothesis is to be explored, chromium picolinate (which has some PCOS/insulin-resistance literature) may offer a more biologically grounded starting point than chromic chloride specifically.
- Re-evaluate predicted indication ranking: Given that three of the top 10 predictions are glaucoma subtypes and likely represent knowledge-graph clustering artefacts, consider whether the amenorrhea (rank 3) or peripheral arterial disease (rank 7) indications — which carry more plausible metabolic mechanistic links — should be prioritised for deeper exploration instead.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.